Jefferies Maintains Buy on Veradermics, Raises Price Target to $182

Benzinga Newsdesk www.benzinga.com Positive 67.0%

Neg 0% Neu 0% Pos 67%

Jefferies analyst Roger Song maintains Veradermics (NYSE:MANE) with a Buy and raises the price target from $138 to $182.